These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 18297955

  • 1. Targeted therapies: a new generation of cancer treatments.
    Gerber DE.
    Am Fam Physician; 2008 Feb 01; 77(3):311-9. PubMed ID: 18297955
    [Abstract] [Full Text] [Related]

  • 2. Review: side effects of approved molecular targeted therapies in solid cancers.
    Widakowich C, de Castro G, de Azambuja E, Dinh P, Awada A.
    Oncologist; 2007 Dec 01; 12(12):1443-55. PubMed ID: 18165622
    [Abstract] [Full Text] [Related]

  • 3. Molecular targeted therapies for solid tumors: management of side effects.
    Grünwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J.
    Onkologie; 2009 Mar 01; 32(3):129-38. PubMed ID: 19295254
    [Abstract] [Full Text] [Related]

  • 4. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
    Esper P, Gale D, Muehlbauer P.
    Clin J Oncol Nurs; 2007 Oct 01; 11(5):659-66. PubMed ID: 17962174
    [Abstract] [Full Text] [Related]

  • 5. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK.
    J Clin Oncol; 2003 May 15; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [Abstract] [Full Text] [Related]

  • 6. Toxicity of targeted therapy in non-small-cell lung cancer management.
    Ricciardi S, Tomao S, de Marinis F.
    Clin Lung Cancer; 2009 Jan 15; 10(1):28-35. PubMed ID: 19289369
    [Abstract] [Full Text] [Related]

  • 7. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V, Deray G.
    Anticancer Drugs; 2009 Jan 15; 20(1):81-2. PubMed ID: 19343005
    [Abstract] [Full Text] [Related]

  • 8. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
    Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME.
    Oncologist; 2007 May 15; 12(5):610-21. PubMed ID: 17522250
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular toxicity of molecularly targeted agents.
    Strevel EL, Siu LL.
    Eur J Cancer; 2009 Sep 15; 45 Suppl 1():318-31. PubMed ID: 19775628
    [No Abstract] [Full Text] [Related]

  • 10. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS, Ioannidis GN, Ardavanis AG.
    Acta Oncol; 2009 Sep 15; 48(7):964-70. PubMed ID: 19734999
    [Abstract] [Full Text] [Related]

  • 11. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R, Wilcken N, Shannon J.
    Aust Fam Physician; 2008 Sep 15; 37(1-2):45-9. PubMed ID: 18239753
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS, English JM.
    Nature; 2006 May 25; 441(7092):457-62. PubMed ID: 16724058
    [Abstract] [Full Text] [Related]

  • 13. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
    Ellis LM, Hicklin DJ.
    Clin Cancer Res; 2008 Oct 15; 14(20):6371-5. PubMed ID: 18927275
    [Abstract] [Full Text] [Related]

  • 14. Targeted anti-cancer therapy in the elderly.
    Gonsalves W, Ganti AK.
    Crit Rev Oncol Hematol; 2011 Jun 15; 78(3):227-42. PubMed ID: 20599391
    [Abstract] [Full Text] [Related]

  • 15. VEGF-targeted therapy: mechanisms of anti-tumour activity.
    Ellis LM, Hicklin DJ.
    Nat Rev Cancer; 2008 Aug 15; 8(8):579-91. PubMed ID: 18596824
    [Abstract] [Full Text] [Related]

  • 16. Skin reactions to the new biologic anticancer drugs.
    Myskowski PL, Halpern AC.
    Curr Opin Support Palliat Care; 2009 Dec 15; 3(4):294-9. PubMed ID: 19797958
    [Abstract] [Full Text] [Related]

  • 17. Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
    de Castro G, Awada A.
    Curr Opin Oncol; 2006 Jul 15; 18(4):307-15. PubMed ID: 16721122
    [Abstract] [Full Text] [Related]

  • 18. Heart failure caused by molecularly targeted therapies for cancer.
    Jarkowski A, Glode AE, Spangenthal EJ, Wong MK.
    Pharmacotherapy; 2011 Jan 15; 31(1):62-75. PubMed ID: 21182360
    [Abstract] [Full Text] [Related]

  • 19. Overview of targeted therapies in oncology.
    Kalyn R.
    J Oncol Pharm Pract; 2007 Dec 15; 13(4):199-205. PubMed ID: 18045779
    [Abstract] [Full Text] [Related]

  • 20. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J, Herbst RS, Onn A.
    Clin Lung Cancer; 2008 Dec 15; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.